Joshua Lang

Joshua Lang
About Joshua Lang

Immunotherapy activates the body’s own immune system to attack tumor cells. Dr. Lang’s research proposal focuses on increasing the power of immunotherapy for the treatment of advanced prostate cancer. Dr. Lang will study specialized prostate cancer vaccines that are designed to turn a patient’s normal immune response against prostate cancer. He will study medications that can alter the pattern of gene expression in patient immune cells which in turn may enhance them to seek out, and destroy prostate cancer cells at metastases. The overall goal is to combine the medicines that change gene expression patterns with other immune system stimulating drugs and antibodies, and deliver better outcomes in advanced disease.


The 2010 Dendreon – PCF Young Investigator Award

Joshua Lang, MD, MS

University of Wisconsin Carbone Comprehensive Cancer Center – Madison, WI


Douglas McNeel, MD, PhD, Associate Professor of Medicine, Section of Hematology/Oncology at the University of Wisconsin Carbone Comprehensive Cancer Center.